Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Mitchell

Physician Assistant Reston, VA Physician Assistant

NPI 1427421411 CMS profile 10825885

1860 Town Center Dr Ste 130, Reston, VA 20190

Open in the dashboard

General payments

$16,733

847 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Mitchell of Reston, VA is reported in the CMS Open Payments database as having received $16,733 across 847 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,462 121
2024 General $2,416 104
2023 General $4,102 216
2022 General $4,035 218
2021 General $3,717 188

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Mitchell
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kelly Mitchell were reported at $2,462. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kelly Mitchell Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,717 $132 $37–$438 $132
2022 $4,035 $155 $48–$522 $149
2023 $4,102 $167 $52–$557 $160
2024 $2,416 $178 $55–$600 $164
2025 $2,462 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,869 142 payments
  2. Amgen Inc. $2,008 95 payments
  3. Novartis Pharmaceuticals Corporation $1,765 77 payments
  4. Janssen Biotech, Inc. $1,687 71 payments
  5. UCB, Inc. $1,457 97 payments
  6. Mallinckrodt Hospital Products Inc. $812 36 payments
  7. AstraZeneca Pharmaceuticals LP $791 34 payments
  8. GlaxoSmithKline, LLC. $686 35 payments
  9. Pfizer Inc. $594 45 payments
  10. Lilly USA, LLC $593 37 payments
  11. Other $3,471 178 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,650 843 payments
  2. Education $83 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,303 112 payments
  2. TREMFYA $1,224 37 payments
  3. SIMPONI ARIA $1,077 48 payments
  4. Cimzia $940 62 payments
  5. COSENTYX Immunology $827 40 payments
  6. ACTHAR $812 36 payments
  7. COSENTYX Dermatology $809 32 payments
  8. SAPHNELO $754 32 payments
  9. Otezla $722 32 payments
  10. Enbrel $686 30 payments
  11. Other $10,311 595 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,690

Median for Physician Assistant: 241

Drug cost

$1,105,951

Median for Physician Assistant: $4,110

Branded share of claims

27.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 26 $282,708
Humira(Cf) Adalimumab Brand 11 $251,650
Rinvoq Upadacitinib Brand 32 $251,153
Enbrel Sureclick Etanercept Brand 21 $148,872
Xeljanz Xr Tofacitinib Citrate Brand 11 $63,938
Otezla Apremilast Brand 12 $61,567
Hydroxychloroquine Sulfate Generic 241 $11,415
Methotrexate Methotrexate Sodium Brand 222 $8,121
Leflunomide Generic 48 $4,271
Celecoxib Generic 115 $3,866

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $380
$380 32 —
TREMFYA
  • Janssen Biotech, Inc. $302
$302 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $250
$250 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $248
$248 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $187
$187 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

847 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record